CellCept Dosage & Drug Information

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Concise Prescribing Info

Contents

Mycophenolate mofetil

Indications/Uses

Concomitant use w/ cyclosporin & corticosteroids for prophylaxis of acute organ rejection in patients receiving allogeneic renal, cardiac & hepatic transplants. Concomitant use w/ corticosteroids for induction & maintenance treatment of lupus nephritis.

Click to view CellCept detailed prescribing information

Dosage/Direction for Use

Renal transplant; induction & maintenance treatment of lupus nephritis 1 g bd. Cardiac & hepatic transplant 1.5 g bd.

Click to view CellCept detailed prescribing information

Overdosage

View CellCept overdosage for action to be taken in the event of an overdose.

Administration

Should be taken on an empty stomach: In stable renal transplant patients, may be administered w/ meals if necessary. Swallow whole, do not chew/crush/open.

Contraindications

Hypersensitivity to mycophenolate mofetil or mycophenolic acid (MPA). Women of childbearing potential not using highly effective contraceptive methods. Pregnancy & lactation.

Click to view CellCept detailed prescribing information

Special Precautions

Avoid use in avoided in patients w/ hypoxanthine-guanine phosphoribosyl-transferase deficiency eg, Lesch-Nyhan & Kelley-Seegmiller syndrome; incidence of digestive system adverse events. Increased risk of lymphomas & other malignancies; avoid exposure to sunlight & UV light. Pure red cell aplasia (PRCA); immunosuppressed patients. Monitor blood counts wkly during 1st mth, twice mthly for 2nd & 3rd mth & mthly through 1st year; neutropenia. Not to be used concomitantly w/ azathioprine; switching combination therapy from regimens containing immunosuppressants; drugs interfering MPA's enterohepatic cycle. Avoid use of live attenuated vaccines & doses >1 g bd to renal transplant patients w/ severe chronic renal impairment. May affect ability to drive & use machines. Severe renal impairment. Women of childbearing potential should use highly effective contraception prior to, during & for 6 wk after last dose. Elderly.

Click to view CellCept detailed prescribing information

Use In Pregnancy & Lactation

Click to view CellCept detailed prescribing information

Adverse Reactions

Bacterial, viral & fungal infections; benign skin neoplasm, neoplasm, skin cancer; anemia, ecchymosis, leukocytosis, leukopenia, pancytopenia, thrombocytopenia; acidosis, hypercholesterolemia, hyperglycemia, hyperkalemia, hyperlipidemia, hypocalcemia, hypokalemia, hypomagnesemia, hypophosphatemia, decreased wt; confusional state, depression, insomnia; dizziness, headache, hypertonia, paresthesia, somnolence, tremor; tachycardia; HTN, hypotension, venous thrombosis; cough, dyspnea, pleural effusion; abdominal pain, colitis, constipation, decreased appetite, diarrhea, dyspepsia, esophagitis, flatulence, gastritis, GI hemorrhage & ulcer, ileus, nausea, stomatitis, vomiting; increased blood alkaline phosphatase, lactate dehydrogenase & hepatic enzyme, hepatitis; alopecia, rash; arthralgia, muscular weakness; increased blood creatinine & urea, hematuria; asthenia, chills, edema, hernia, malaise, pain, pyrexia.

Click to view CellCept detailed prescribing information

Drug Interactions

Higher MPAG & acyclovir plasma conc. Increased MPAG & ganciclovir conc. Decreased MPA exposure w/ Mg & Al hydroxides antacids, PPIs eg, lansoprazole, pantoprazole; rifampicin, ciclosporin A. Reduced MPA AUC w/ cholestyramine, norfloxacin, metronidazole. Increased MPA exposure w/ isavuconazole. Decreased MPA conc w/ telmisartan. Reduced pre-dose MPA conc w/ ciprofloxacin or amoxicillin + clavulanic acid. Raised MPAG plasma AUC w/ probenecid. Decreased MPA C_max & AUC w/ sevelamer.

Click to view CellCept detailed prescribing information

Caution For Usage

For caution against possible variation of physical aspect of medicine... Click to view CellCept detailed prescribing information

Storage

View CellCept storage conditions for details to ensure optimal shelf-life.

Description

View CellCept description for details of the chemical structure and excipients (inactive components).

Action

View CellCept mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Immunosuppressants

ATC Classification

L04AA06 - mycophenolic acid ; Belongs to the class of selective immunosuppressive agents. Used to induce immunosuppression.

Regulatory Classification

Presentation/Packing

Form

CellCept cap 250 mg

Packing/Price

100's

Form

CellCept tab 500 mg

Packing/Price

50's

CellCept

mycophenolic acid

Manufacturer:

Roche

Distributor:

Zuellig Pharma